Cellectis SA

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

NEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Cellectis  (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop innovative therapeutics for the treatment of serious diseases, announced today preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients (HbSS) at the 63rd Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

ACADIA Pharma

Intellia Therapeutics

Novavax

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.

Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells. The expanded agreement will include a new CAR target and development in China by Cytovia's joint venture entity, CytoLynx Therapeutics.

Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

Cytovia Commits to Additional Milestones and Equity grant Cytovia Commits to Additional Milestones and Equity grant

Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage gene-editing company employing its core technology to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in the field of immuno-oncology and gene-edited hematopoietic stem cells in other indications, announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin, being developed for patients with mesothelin-expressing solid tumors.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results - Earnings Call Transcript

•   Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, today announced the release of two abstracts, which were accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11-14, 2021. The Company will present updated preliminary clinical data from its BALLI-01 clinical trial in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), and preclinical data for TALGlobin01 for patients with HbSS Sickle Cell Disease (SCD).

Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01

NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced that it will report its financial results for the third quarter and first nine-month period ending September 30, 2021, on Thursday, November 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EDT / 2:00 PM CET on Friday, November 5, 2021, prior to the open of the US market.

Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, in collaboration with Professor Toni Cathomen, scientific director at the Center for Chronic Immunodeficiency Medical Center at the University of Freiburg, Germany, will present two oral presentations at the European Society of Gene and Cell Therapy (ESGCT) Congress to be held virtually from October 19-22, 2021.

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting (SITC 2021), to be held in Washington, D.C. and virtually on November 10 to 14, 2021.

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Beam Therapeutics

bluebird bio

CRISPR Therapeutics

Editas Medicine

Regeneron Pharmaceuticals

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.

7 Gene Editing Stocks Promising to Change our DNA

NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.

Cellectis Announces Participation in Five Investor Conferences

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed orrefractory multiple myeloma patients.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d'édition du génome spécialisée dans les essais en immuno-oncologie en phase clinique utilisant des cellules T allogéniques à récepteur d'antigène chimérique (CAR) et des essais de thérapie génique pour les maladies monogéniques, publiera ses résultats financiers pour le deuxième trimestre et le premier semestre 2021 se terminant au 30 juin 2021, le vendredi 6 août 2021 après la clôture du marché aux États-Unis.

Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic diseases, announced that it will report its financial results for the second quarter and first six-month period ending June 30, 2021, on Thursday, August 5, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EDT / 2:00 PM CET on Friday, August 6, 2021, prior to the open of the US market.

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

Phase I trials mean more usual for Cellectis. Cellectis is pursuing low-hanging fruit indications.

Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential

Calyxt

Sangamo Therapeutics

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century appeared first on InvestorPlace.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries.

CRISPR: 4 Emerging Players

Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer. Cellectis offers a specialization in gene-editing, enabling their CAR-T product candidates to have additional safety and efficacy attributes alongside healthy tissue-protective measures, enabling high tolerance oncology therapeutics.

Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

Cellectis SA (NASDAQ: CLLS) has announced four new preclinical UCART product candidates targeting solid tumors - UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (mesothelin), UCARTMUC1 (Mucin 1), UCARTFAP (cancer-associated fibroblasts). Additionally, the company announced its genome surgery hematopoietic stem cells platform, HEAL, which focuses on monogenic diseases like sickle cell anemia.

Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors

• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting  B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin),  UCARTMUC1 (targeting Mucin 1), UCARTFAP (targeting Cancer Associated Fibroblasts)

Cellectis' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders' General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France.

Cellectis S.A. Reports Results from Annual Shareholders' General Meeting Held on June 1, 2021

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncology, and Sanofi (Euronext: SAN – NYSE: SNY), today entered into a partnership agreement and a supply agreement regarding alemtuzumab, an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis sponsored UCART clinical trials.

News for Cellectis SA Stock (CLLS)